Skip to main content
. 2021 Aug 2;12:694698. doi: 10.3389/fphar.2021.694698

FIGURE 4.

FIGURE 4

Meta-analysis of observational studies of major adverse cardiovascular events (A) and all-cause mortality (B) with other P2Y12 inhibitors and proton pump inhibitor use.